A rRNA hybridization-based approach for rapid and accurate identification of diverse
fungal pathogens

Elizabeth A. Yee[1*] Brooks J. Burt[2*] Poppy C. S. Sephton- Clark[2,3] M. Lauren Donnelly-Morrell[1,4],
Isaac H. Solomon[5], Evan Mojica[7], Christina A. Cuomo[1, 6#] Roby P. Bhattacharyya[1, 8#]
[1]Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge MA 02142 USA
[2]Genomic Center for Infectious Disease, Broad Institute of MIT and Harvard, Cambridge MA 02142 USA
[3]Valo Health, 75 Hayden Avenue Suite 200, Lexington, MA 02421 USA
[4]Department of Pathology, Massachusetts General Brigham, Harvard Medical School, Boston, MA USA
[5]Department of Pathology, Brigham and Women's Hospital, Harvard Medical School Boston, MA 02115 USA
[6]Department of Molecular Microbiology and Immunology, Brown University, Providence RI 02912 USA
[7]Microbiology Laboratory, Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
[8]Infectious Disease Division, Department of Medicine, Massachusetts General Hospital, Boston MA 02114 USA
*Denotes Co-First authorship EAY and BJB contributed equally.
#To whom correspondence should be addressed

15
16

Abstract

Invasive fungal infections are a global threat; early diagnosis is critical for patient outcomes, but

current diagnostic measures remain notoriously slow. Here we extend our multiplexed,

hybridization-based rRNA-targeted strategy for rapid, sensitive pathogen identification,

previously designed for diverse bacteria and *Candida* species, to identify diverse fungal

pathogens. We created a set of 91 probes targeting 86 medically relevant fungal species,

designed to recognize regions of differential conservation across taxonomic groupings, from

class- to species-specific probes. We assessed assay performance across a Training Set of 93

clinical isolates spanning 32 species of common fungal pathogens across 18 genera, with

Pearson correlations of probeset reactivity profiles (PSRPs) accurately identifying the pathogen

at the species, genus, and class level with 83%, 93%, and 94% accuracy, respectively, in a

leave-one-out analysis. We developed a more sophisticated classifier on this Training Set, using

taxonomic categories to select progressively more informative probes at each taxonomic level.

After optimization, we assessed performance on an independent Validation Set of 54 clinical

isolates spanning the same species as the Training Set, with 91%, 94%, and 98% at the

species, genus, and family levels respectively. We piloted our assay on formalin-fixed paraffin-

embedded (FFPE) tissue, demonstrating rapid, culture-independent fungal identification from

this high-value clinical sample type, often the sole specimen available. The assay requires <30

minutes hands-on time (or <65 minutes from FFPE tissue), returning results in <8 hours from

cultured specimen or FFPE tissue to answer on an RNA detection platform available in clinical

laboratories.

Introduction

Invasive fungal infections (IFIs) are a growing threat to human health, accounting for 1.6 million global deaths annually.[1] Advances in immunosuppressive drugs and chemotherapy have resulted in larger immunocompromised populations vulnerable to opportunistic pathogens. [2–4] Early diagnosis of fungal infections is critical for patient outcome, but is notoriously slow, relying heavily on expert clinical mycologists identifying morphology from cultured or fixed patient specimens.[1,5,6] As such, healthcare systems are in need of rapid and accurate diagnostic tools to identify fungal infections.[3-5]

Progress has been made in fungal diagnostics using several different modalities. Serological testing can help diagnose IFIs by detecting fungal antigens, or host antibodies reflecting exposure, but many assays have cross reactivity.[7,8] Serology platforms often have a quick turnaround time and no culturing requirement, but are limited by a narrow species range or high false positivity rate for more general fungal markers such as 1,3-β-D-glucan.[3,7,9,10] Widely used for bacterial identification, matrix assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry is gaining traction as a method of fungal identification.[7,11,12,13] Although this method is easy to run, it requires culture growth which is not always possible, and identification is complicated by variable surface proteome expression across the fungal life cycle, making fungi harder to identify against reference databases.[5,7,14]

As costs fall and efficiency increases, sequencing is increasingly used for fungal identification. Targeted amplicon sequencing of the internal transcribed spacer region (ITS), ribosomal RNA genes (rDNA), or additional highly conserved genes has been widely adopted by reference laboratories to discriminate between fungal species.[5,9,15,16] However, fungal DNA in primary clinical samples is often very scarce, requiring amplification that can result in false positives from low-level contaminants.[17] Conversely, false negatives can occur due to inhibition of PCR

enzymes.[17] Despite these improvements in fungal diagnostics, no single strategy or commercial

test can identify a wide variety of fungal organisms rapidly and accurately. Additionally,

sequencing assays are often send-out tests with lengthy turnaround times, limiting their clinical

utility. There is thus a critical need to explore diagnostic options that balance sensitivity,

specificity, scalability, and breadth of coverage.

Previously, we described a novel rRNA-based strategy for rapid, sensitive bacterial identification

directly from primary clinical samples or cultured blood samples utilizing a commercially

available assay platform for multiplexed hybridization-based RNA quantification

(NanoString).[18,19] This assay, which we named phylogeny-informed rRNA-based strain

identification (Phirst-ID), uses 192 probes targeting regions in the 16S and 23S rRNA from 98

medically relevant bacterial species.[18] Each target region was selected for specificity at the level

of a pathogenic species, or higher taxonomic levels.[18] The fluorescent read-out from these

probes results in differential hybridization that creates a unique "fingerprint" pattern of reactivity

that accurately identifies each species.[18] We later extended this approach to yeast, designing a

Candida Phirst-ID probeset that discretely identified 11 medically relevant *Candida* species with

100% accuracy by targeting the 18 and 28S rRNA subunits.[20] By recognizing the highly

abundant rRNA itself, rather than the DNA that encodes it, this approach can detect and identify

<30 cells without amplification.[20]

Here we further expanded this approach by creating a panel of 91 probes targeting 86 medically

relevant fungi, targeting regions of the 18S and 28S rRNA subunits with differential conservation

across taxonomic groupings, ranging from class to species (**Fig. 1**). This species list targeted

the Fungal Priority Pathogen List from the WHO and intentionally excluded 56 common

environmental fungi as an outgroup in the design process. The resulting "Pan-Fungal Phirst ID"

assay was first tested on a curated Training Set of 93 clinical isolates, then verified on a

Validation Set of 54 independent isolates. Using Pearson correlations, we achieved a positive

species match rate of 84%. For some isolates, higher order taxonomic probes dominated the

signature, compromising accuracy by overpowering more specific signals from genus and

species level probes. To address this, we developed an optimized classifier, increasing species-

level accuracy to 89%. To assess potential utility on primary specimens, we piloted the assay on

archived clinical formalin-fixed paraffin-embedded (FFPE) tissue samples.

Materials and Methods:

Probeset Design

We compiled a comprehensive list of medically relevant fungi, using the WHO Fungal Priority

Pathogen list as a guide, for training and validation of our probeset. We collated the 18S and

partial 28S sequences for 86 medically relevant fungal species primarily from the Silva

database; where sequences were too short or not available, we retrieved regions from NCBI

assemblies for the following: *Mucor circinelloides*, *Emergomyces orientalis*, *Epidermophyton*

floccosum, *Coccidioides posadasii*, *Coccidioides immitis*, *Histoplasma capsulatum*,

Emergomyces pasteurianus, *Exophiala dermatitidis*, *Trichophyton indotiniae*, *Kodamaea*

ohmeri, *Wickerhamomyces anomalus*, *Kluyveromyces marxianus*, *Malassezia dermatis*,

Enterocytozoon bieneusi. Additional 18S sequences were selected from Silva for 56

environmental fungal species to serve as an outgroup during probe design to minimize

unintentional cross reactivity. Due to inconsistent annotation of the 28S sequences, we were

unable to obtain full-length 28S sequences for all ingroup species. For outgroup species, we

were only able to obtain reliable 18S sequences. We compiled a full taxonomic classification of

each species (**Fig. S1, Table S1**). Employing a similar strategy used in the Pan-Bacterial Phirst-

ID probeset design[18]. We profiled each desired target sequence using NanoString's proprietary

probe design algorithm to identify all putative pairs of consecutive 50mer probe-binding regions

that meet parameter specifications. Specifically, probe sequences are assessed for predicted

binding kinetics, thermodynamics, secondary structure, and sequence composition for the

desired targets while minimizing predicted cross-reactivity against non-targeted outgroup

species, or the human genome. For species-specific probes, outgroups included and all other

pathogenic and environmental fungi; we sought probes predicted to bind exclusively to the

targeted species in a given rRNA region, whose sequence was unique to that species (**Table**

S2). For probes targeting higher taxa (genus, family, order, or class), we sought probes

predicted to bind all members of that taxon, (including either pathogen or environmental fungi,

since including only pathogens would likely impose unrealistic constraints in sequence space),

while excluding all outgroups not belonging to that taxon. For *Candida* species, which have

undergone considerable phylogenetic reclassification of late, we kept the clinically familiar

genus classification *Candida* for all (*Candida, Candidozyma, Pichia, Nakeseomyces,*

Meyerozyma, etc.), which likely changed design constraints on the genus-level probe. This

decision could be revisited in future iterations of the probeset.

The final probeset includes 60 probes designed to be species-specific, as well as 31 probes

designed to recognize rRNA regions conserved across higher taxonomic groupings, including

14 genus-level probes, 8 family probes, 5 order probes, and 4 class probes (**Fig. S1**). During

testing, the *Mucor circinelloides* 28S probe yielded substantial cross-reactivity against nearly all

tested species. We thus removed this probe analytically, resulting in a final set of 91 probes

used for all analyses (**Table S1**). Also included in the probeset are 12 control probe pairs (6

negative, 6 positive) directed at External RNA Controls Consortium (ERCC) targets as

previously described.[18] The 6 positive controls are directed at ERCC spike-ins included in every

hybridization reaction at pre-specified concentrations; the 6 negative controls are directed at

biorthogonal targets not included in the hybridization.

Sample acquisition

Most of our clinical isolates were collected from the Massachusetts General Hospital (MGH)

Clinical Microbiology Laboratory, for both Training and Validation Sets. These isolates were

provided as cell pellets suspended in Trizol solution after culture isolation on standard fungal

media in the clinical laboratory. Isolates were identified through standard clinical microbiology

workflows as part of routine patient care and shared with the investigators under Mass General

Brigham Institutional Review Board protocol 2015P002215. In keeping with diagnostic

limitations in these standard clinical workflows, some isolates were only identified to the genus

level, including all *Curvularia*, *Coccidioides*, *Fusarium*, *Cunninghamella*, *Mucor*, *Rhizopus* and

Talaromyces isolates. Some *Candida* species were supplemented from our own laboratory

collection and the Antibiotic Resistance Isolate Bank drug resistant *Candida* (CAN) and *Candida*

auris (CAU) collections. Additional samples were generously shared with us from the following

sources: *Histoplasma capsulatum* cell pellets suspended in Trizol from Dr. Sinem Beyhan

(JCVI)[21], *Pneumocystis jirovecii* gDNA from human autopsy samples from Dr. Joseph Kovacs

(NIH), and *Blastomyces dermatiditis* purified RNA*, Cryptococcus gattii, Paracoccidioides*

brasiliensis, Sporothrix schenckii and *Talaromyces marneffei* purified gDNA from the Fungal

Genomics Group at the Broad Institute.[21–25] Per our biosafety regulations, all cultured isolates

from external collaborators were received in Trizol. If we were unable to obtain a cultured

isolate, we utilized either gDNA or RNA as available. Coded/de-identified FFPE tissue samples

were obtained from the Brigham & Women's Hospital (BWH) Pathology Department, after visual

screening to identify archived clinical samples from 2019-2025 with varying levels of visible

fungal forms (ranging from rare to confluent). Fungal identification of these autopsy and surgical

pathology cases were based on integration of all available laboratory results from anatomic

pathology histochemical stains, culture isolation from concurrently collected tissue samples, and

molecular testing of FFPE tissue, frozen tissue, or culture isolates.[26] **Table S3** lists all samples

and sources.

Training and Validation Set parameters

To test the Pan-Fungal Phirst-ID probeset, we acquired as many samples from our fungal

pathogen list as possible. In all, we collected 171 samples (isolates, gDNA, or RNA) from 53

species. To assess assay performance as rigorously as possible, we divided these samples into

Training and Validation Sets based on the number of samples of each species we were able to

collect (**Table S3a, b**). In the ideal case, we included 3 samples of the same genus and species

in the Training Set, with any remaining samples (up to 3 more) used for validation. If we were

only able to obtain 3 samples total, we included 2 in the Training Set and kept the third in the

Validation Set (**Table S3a, b**). In the end, this led to 93 samples across 33 species in the

training set, with 54 samples across 32 species in the Validation Set. For 21 additional species,

we were only able to obtain 1 (n = 18) or 2 (n = 3) samples. Since this was insufficient to

assess classification accuracy, we did not include these samples in either the Training or

Validation Sets, but we do report their results separately. For assessment of classification

performance, background subtraction and normalization was carried out exactly as previously

described,[18,20] and classifiers were developed and iterated using only data from the Training

Set, before being run on the Validation Set with no changes to any analytical processes. All

Validation Set analyses were done with authors blinded to sample identification until after

predictions were finalized. For FFPE samples, pathology co-authors (MLD-M and IHS) selected

samples, whereas the remaining co-authors (notably EAY, BJB, CAC, RPB) stayed blinded to

the identities of all species until all thresholding decisions, classification algorithms, and identity

predictions were finalized.

Sample processing

<u>Cultured isolates collected from MGH</u>

Clinical isolates were received from the clinical microbiology laboratory in Trizol and processed

as follows: 125µL of each sample in Trizol was added to a 2ml screw cap tube (MP

Biomedicals, CAT# 76044-692) with an additional 125µL of Trizol reagent (ThermoFisher

CAT#15596026) with 100µl of 0.1uM zirconia/silica beads (Biospec, CAT# 11079101z), then

bead-beaten for 2 rounds on the FastPrep 5G (MP Biosciences) for 90s, at 10 m/s. 50µL of

chloroform was added to each sample, inverted, and the mixture was spun down at 12,000 x g

for 15 minutes at 4C. 50µL of the aqueous phase was transferred to a fresh 1.5 ml Eppendorf

tube. To prevent degradation of the RNA in this crude lysate, 50µL RLT buffer (Qiagen CAT#

79216) with 1% β-mercaptoethanol (β-ME), an irreversible chemical RNase inhibitor, was added

to each lysate prior to storage at -80ºC.

<u>gDNA samples of selected isolates</u>

gDNA samples from the Fungal Genomics group at the Broad Institute were used to assist in

species coverage for members of the Fungal Priority Pathogen list. Approximate concentrations

were measured using the Nanodrop One system (ThermoFisher CAT#ND-ONE-W). Dilutions of

some gDNA samples were made in 1x Phosphate Buffered Saline (PBS) to ensure probe

reactivity patterns were within control cutoffs and max probe limits as described below.

<u>Cultured isolates prepared from ARBank isolates</u>

The ARBank *C. auris* (CAU) and drug-resistant *Candida* (CAN) collections were used to

supplement *Candida* species for Training and Validation sets (**Table S3a, b**). Cultured isolates

prepared in house and were processed as previously described.[20]

NanoString Data generation

Our custom Pan-Fungal Phirst-ID probeset was run using the Elements assay variation on the

standard NanoString assay for multiplexed RNA detection. Briefly, lysates from cultured

organisms were diluted first at a 1:10 ratio in PBS to avoid assay saturation. For gDNA and

RNA samples, dilution was not always necessary depending on the concentration of the

sample. For all samples, 1.5µL of lysate or nucleic acid was incubated with unlabeled probe

pairs for each target (IDT) and Elements TagSet-96 reagents (NanoString CAT#121000608).

Hybridization conditions were standard, except for 2 modifications: lysates were incubated at 95

°C for 2 minutes immediately prior to hybridization to denature secondary structural elements

and disrupt protein binding in rRNA targets, and hybridizations were incubated for one hour

instead of the recommended 16-24 hours, exactly as we have previously done[18,20]. Hybridized

samples were then run on the NanoString nCounter platform and subsequently analyzed using

the nCounter Digital Analyzer.

Cell densities from samples cultured by collaborators, and from paraffin scrolls, were unknown

prior to running on the nCounter platform. We established three parameters to address sample

overloading: (1) positive control signals out of the expected order given known spike-in

concentrations, suggesting cross-reactivity; (2) any negative control value > 100 total read

counts; or (3) maximum probe count >100,000, where saturation might affect relative ratios. If

any of these 3 parameters were met, the affected sample was re-run with increased dilutions

until the issue resolved. The maximum number of re-runs required for a given sample was up to

three to meet our stated parameters. Across training and Validation Sets, 62 lysates required at

least one re-run, with four samples requiring additional runs. All such decisions were made

solely based on these three criteria, prior to any assessment of prediction accuracy.

Data processing and visualization

Raw binding data (counts per probe) were compiled using NanoString nSolver software (v3.0).

Raw counts were normalized using positive and negative control spike-ins provided by

NanoString using custom scripts in R, and background signal for each probe was subtracted

based on the average of three blank lanes, exactly as previously described.[18] Pearson

correlations for the resulting normalized, background-subtracted probeset reactivity profiles

were subsequently calculated across samples using the "cor" function in R (version 4.3.1).

Heatmaps were generated by the Pheatmap package v1.0.12 in R. Probes and samples were

arranged phylogenetically.

Co-PILOT Classification

We developed a hierarchical classification model based on Pearson correlations (**Fig. S4**)

termed **Co**mplementarity-based **P**hylogeny-**I**nformed **L**evel-**O**riented **T**raversal (Co-PILOT),

coded entirely in R (version 4.3.1 github) Initial Pearson correlations were calculated for each

isolate to identify most similar samples based on probe-binding signatures. The taxonomic

group (starting with class) was then found for the closest match. All other isolates not in this

taxonomic group were then removed, as were probes not specific to that group (**Fig. S4a-b**).

This process was repeated until the species level, or if there were no more samples to compare

to. The Co-PILOT algorithm was developed and iterated using only our Training Set, then

deployed without modification on our Validation Set, considering each Validation sample one at

a time and using matches to the Training Set as its basis for identification decisions. When the

best match was to a sample from the MGH clinical laboratory for which identification was only

determined to the genus level, Co-PILOT was unable to make a species prediction but could

predict identity to the genus level.

Pilot study of FFPE samples

FFPE scrolls (60μm per block in each tube) were obtained from the Brigham and Women's

Hospital Pathology Department. Samples FP001-FP012, FP016-019 were processed using the

RNeasy FFPE kit (Qiagen CAT# 73504), per NanoString recommendations. Given inconsistent

results at an interim assessment, we processed the remaining samples (FP020-030) using the

quick DNA/RNA FFPE kit (Zymo CAT# R1009) (**Table S3c**). Samples were first deparaffinized

using proprietary deparaffinization solutions provided by each kit followed by heating tissue to

either 56ºC followed by 80ºC (Qiagen) or 54ºC (Zymo), separating wax from tissue. Prior to

moving to column purification, samples underwent two rounds of bead beating as described

previously and spun down at 13,000xg for 1 min before loading onto column for final purification.

All lysates were stored at -80ºC after elution. FFPE samples were analyzed as a separate

dataset relative to Training and Validation Sets. Compiled FFPE data was analyzed for species

classification against a "superset" containing Training, Validation, and rare incidence isolate

datasets, mirroring how we would expect to deploy this method on primary tissue samples going

forward. After visual inspection of resulting PSRPs for all samples, we had low confidence in

samples that had <1000 raw counts from any probe (see **Fig. S9**). Using this metric as a

baseline, we divided samples based on their max probe counts into low and high confidence

groups, though we report Co-PILOT's best match for each sample in each group. As described

above, if a species identification was not defined for a given sample, the final best match was

made at the genus level.

ITS sequencing workflow to confirm species ID

Clinical isolates were received in Trizol, and additional cultured material was unavailable. For

those unable to be identified to the species level by standard workflows, we sought to obtain

genomic DNA (gDNA) to enable ITS sequencing. As these samples were intended for extraction

of RNA rather than DNA, we omitted the chloroform extraction, which improves partitioning of

RNA from gDNA, hoping this would result in enough gDNA for PCR. 100µL of remaining

inactivated sample not used in original lysate prep was combined with an additional 300µL of

Trizol, then underwent 2 rounds of bead beating as previously described, then processed using

the Zymo DirectZol RNA kit (CAT#: R2050). Samples were eluted in 25ul of Elution buffer as

specified. ITS1 and ITS2 regions were amplified using the NEB Q5 hot start master mix

(CAT#:M0491S) using primers and cycling conditions as previously described.[20,27] PCR

products were visualized on an E-Gel Power Snap Electrophoresis Device (Invitrogen

CAT#:G8100) using a 1% Agarose E-Gel (Invitrogen CAT#: G401001) for the presence of

bands for ITS1 or ITS2. Samples with bands corresponding to either ITS1, ITS2 or both were

purified using the Zymo DNA Clean and Concentrate (CAT#: D4033) and sent to Plasmidsaurus

for amplicon sequencing. Results were first analyzed in Geneious and trimmed for quality using

standard parameters; trimmed sequences then were submitted to UNITE using the regular

output style and 2 sequence alignments per sample for analysis.[28]

Results

Pathogen selection and Pan-Fungal Phirst-ID probeset design

We selected 86 medically relevant fungi using the WHO Priority Pathogen List as key species to

target with our panel, and an outgroup of 56 environmental and non-medically relevant fungi

(**Table S1**). Targeting species-specific variable regions of the 18 and 28S rRNA subunits, we

designed 61 species-specific probes, one of which was removed from analyses due to

excessive cross-reactivity (see Methods). For the remaining targeted species, we could not

design a species-specific probe within the constraints of the NanoString assay due to

phylogenetic constraints. For the closely related *Candida albicans* and *Candida dubliniensis,*

and *Aspergillus fumigatus* and *Aspergillus clavatus,* we designed single probes predicted to

selectively recognize each pair of species.

As previously described,[18] we also designed higher-order taxonomic probes to improve

accuracy in identifying target species through multiple recognition events, creating a unique

probeset reactivity profile (PSRP) that serves as a "fingerprint" for each isolate tested. These

higher taxonomic order probes can also enable partial characterization of pathogens not

included in probeset design.[18] To do so, we analyzed the 18 and 28S sequences for variable

regions shared across species of the same genus, family, order, or class conserved enough to

recognize all members within a given taxonomic classification, while excluding outgroup

species.[18,20] This resulted in 14 genus probes, 8 family probes, 5 order probes and 4 class

probes, culminating in a Pan-Fungal Phirst-ID probeset of 91 probes (**Fig. 1**; **Fig. S1, Table S2**).

Collation of Training and Validation Sets

To rigorously test our panel, we collected isolates from 18 of 19 members of the WHO Fungal

Priority Pathogen List, as well as 35 other clinically important species available from the MGH

clinical microbiology laboratory. Isolates were split into Training and Validation Sets based on

availability, with three isolates per species used for Training when possible and all remaining

isolates used for Validation; when only three total isolates were available, two were used for

Training and one for Validation (**Table S3a, b**; see Methods). Our Training Set contains 93

isolates spanning 18 unique genera and 26 defined species, and our Validation Set contains 54

isolates with the same genus and species numbers. For 7 genera, we were unable to get

species characterization from the MGH clinical lab, due to standard clinical identification

methodology. In addition, we collected several clinical isolates that were too rare (n = 1 or 2 in

our collection) to include in our Training and Validation rubric. Though unable to rigorously

validate classification performance, we tested 24 of these isolates, spanning an additional 14

genera and 21 species not included in our Training and Validation Sets (**Fig. S2**).

Unique reactivity profiles accurately distinguish species

To quantify differences in PSRPs between species, we first calculated a pairwise Pearson

correlation coefficient for each sample against every other sample in the Training Set (**Fig. S3**).

This simple analytical approach incorporates data from all probes tested in the probeset across

the entire reactivity profile. Because of sequence conservation patterns in rRNA genes, PSRPs

of this probeset should reflect species identity. The strongest correlations should exist within

isolates of the same species, whereas non-species matched pairs should have lower correlation

coefficient (**Fig. 2**).[18,20] In a "leave one out" analysis for all isolates in the training set, 83%

matched best to members of the same species, with most mismatches occurring to closely

related species (**Fig. 3**). For 15 samples not identified to the species level, the best match in all

15 was to the same genus, the closest available taxonomic match in the Training Set. In all,

93% of isolates matched at the genus level, and match rates steadily increased for broader

taxa, reaching 100% at the class level (**Fig. 3a**).

Leveraging taxonomy level information to improve classification accuracy

For many isolates in our training set, the higher taxonomic order probes resulted in greater

signal than the species-specific probes (**Fig. 4a**). One notable example is the *Aspergillus* genus,

where class probes dominated the signal readout compared with species probes (**Fig. 4b**). This

systematic difference in probe binding by taxonomic level of the probe target, despite perfect

complementarity between probe and target, was not observed in bacteria.[18] This posed a

unique challenge to accurate classification by Pearson correlation, which intrinsically weights

higher signals and thus undervalues species-level probes with lower maximal reactivities,

reducing species-level accuracy.

To address this uneven signal distribution across probes targeting different taxonomic levels, we

developed a hierarchical classifier, still based on Pearson correlations but progressing stepwise

through taxonomic classifications. We called this classifier **Co**mplementarity-based **P**hylogeny-

Informed **L**evel-**O**riented **T**raversal (Co-PILOT). This approach begins with the full PSRP, but

traverses down the taxonomic classification, at each step eliminating any species and probes

not included in the best-matched taxon. **Fig S4** illustrates a specific example of how Co-PILOT

analyzes an *Aspergillus* sample, narrowing from all probes and samples (**Fig. S4a**), through

class (best match = *Eurotiomycetes*), order (*Eurotiales*), and family (*Aspergillaceae*)-specific

ones (**Fig. S4b-d**), to only those from the *Aspergillus* genus (**Fig. S4e**). At each level, only

probes and samples relevant to the selected taxon are used to recalculate Pearson correlation

coefficients. The best-matched sample from the Training Set at the final step, usually at the

species level, is taken as Co-PILOT's final identification. If the best match from the Training Set

is a clinical sample only identified to the genus level (e.g., *Mucor* spp.), then Co-PILOT's final

step would be at the genus level. In this manner, the entire probeset is still used to classify each

sample, but at each taxonomic level, only the probes designed to be informative in

distinguishing among members of that taxon are considered. This method allows these more

precise reactivity patterns to inform identity, rather than idiosyncratic differences between

higher-order probes that might otherwise dominate a Pearson correlation. Critically, this novel

classifier was devised and iteratively refined based only on the Training Set, before data from

the Validation Set was examined. Thus, although Co-PILOT improved classification accuracy for

the Training Set (**Fig. S5**), this should be viewed as "over-trained". However, its performance on

the Validation Set represents an independent assessment of classification accuracy.

The Pan-Fungal Phirst ID assay accurately classifies an independent Validation Set of

diverse fungal pathogens

Fifty-four independent clinical isolates, representing the same genera and species as the

Training Set, were tested as a Validation Set for the Pan-Fungal Phirst-ID assay (**Fig. S6**). The

resulting PSRPs for these isolates were compiled into a separate dataset that was only released

for analysis after the entire Training Set had been analyzed and the Co-PILOT algorithm had

been finalized. Pearson correlations identified a similar fraction of species (85%) and higher-

order taxa in the Validation Set as the Training Set (**Fig. 5a, b**). Co-PILOT performed better,

identifying 89.3% of species in this independent Validation Set, with 96.2% concordance at the

family level and >98% for all higher-order taxa (**Fig. 5c**).

Investigation of discrepant classifications in the Validation Set

In the Validation Set, Co-PILOT misidentified 4 samples out of 54, all among species also

misidentified in leave-one-out analysis in the Training Set. Incorrect ID matches were correctly

binned at high order taxonomic levels but mismatched to different but related genera or species.

Specifically, misclassifications were made between *Cryptococcus neoformans* and

Cryptococcus gattii, and between *Scedosporium apiospermum* and *Lomentospora prolificans*.

Both pairs are closely related phylogenetically; *C. gattii* was formerly referred to as a serovar of

C. neoformans,[29,30] and *L. prolificans* was formerly classified as a *Scedosporium*.[31] In examining

reactivity profiles (**Fig. 2, Fig. S6**), despite probes designed to distinguish between each

species pair, no real distinction exists between their PSRPs. For the pair of *Cryptococcus*

species, a probe designed to selectively recognize the *C. gattii* 28S rRNA subunit failed to

generate a signal for either species. This *C. gattii* species-specific probe matches a *C.*

deuterogattii (VGII) sequence. Our training set included one *C. deuterogattii* sample, but this did

not react with the species-specific probe, suggesting this probe has a general binding issue and

should be redesigned and confirmed for alignment and potential reactivity to the other *C. gattii*

species complex members. For *S. apiospermum* and *L. prolificans*, two problems arose in these

closely related species: a probe designed to be specific for the *L. prolificans* 28S subunit cross-

reacted with *S. apiospermum* as strongly as with *L. prolificans*; whereas a probe designed to

selectively recognize the *S. apiospermum* 18S subunit generated no signal for either species.

Relevant family and class probes recognized both species comparably, as expected.

We investigated one additional discrepant classification in the Validation Set, which both

Pearson correlations and Co-Pilot called a *Rhizopus*, but the clinical identification labeled it a

Mucor. On visual inspection, its reactivity pattern clearly resembled the *Rhizopus* from our

Training Set more than the *Mucor* (**Fig. S7**). Given the difficulty in clinically distinguishing

among the *Mucorales* by morphology,[32,33] we pursued ITS sequencing to clarify, which showed

100% match to *Rhizopus microsporus* (**Table S3b**), not a *Mucor* species, consistent with our

assay's call. Reclassifying this isolate as a *Rhizopus* instead of a *Mucor* improves the accuracy

of our Co-Pilot classifications on the Validation Set (to 91%, 94%, and 98% at the species,

genus, and family levels respectively).

Pilot use of Pan-Fungal Phirst-ID on clinical Formalin- Fixed Paraffin- Embedded (FFPE)

tissue samples

Fixation of tissues using formalin and embedding in paraffin blocks is the gold standard method

for preparing human tissues for histopathologic diagnosis, including microorganism

identification.[34,35,36] However, this process prevents subsequent growth of microbes; thus, if

infection is only suspected after tissue fixation (e.g., in a lung nodule removed for suspicion of

neoplasia), culture-based pathogen identification is precluded. Often such samples are obtained

via surgical procedures that are impractical or even dangerous to repeat, meaning pathogen

identification must be done either imprecisely by morphology, or via nucleic acid extraction and

PCR from the fixed tissue.[37,38] Since Pan-Fungal Phirst-ID requires only hybridization and no

enzymology, we hypothesized that it might perform comparably to PCR on crude nucleic acid

preparations from FFPE tissue. We thus investigated the performance of our Pan-Fungal Phirst-

ID probeset on nucleic acids extracted from archived clinical FFPE samples on which fungal

forms were observed via microscopic examination, plus two negative controls with no fungal

forms (**Fig. S8**). Pan-Fungal Phirst-ID correctly identified FFPE samples, largely depending on

the quality of sample and NanoString read counts we were able to extract from each sample.

When plotting heatmaps of read counts, 55% displayed visually poor probe binding behavior;

thus, prior to running Co-PILOT, we opted to exclude these as non-informative and focus our

analysis on samples with sufficient NanoString reads (**Fig. S9**)**.** Of the 12 "high confidence"

samples, 8 were correctly identified, with 2 others notably close: an *A. fumigatus* was called *A.*

clavatus; and a *Madurella tropicana*, not included in our expanded Training Set, matched with

the closest possible phylogenetic match, an environmental *Chaetomium* isolate). We also found

a negative control with a large *Candida albicans* signature (**Fig. 6**), a possible contaminant in

sample collection or processing; the other negative control showed low signal as expected (**Fig.**

S9).

Discussion

Fungal infections are a growing global health problem, and current diagnostic methods are

unable to meet the demands of healthcare systems. Currently available testing measures have

significant limitations from financial burdens for instrument costs or expert personnel, frequent

false positives for biomarkers, and limited organism range for which specific tests are available.

We previously developed a molecular diagnostic approach based on rRNA hybridization, Phirst-

ID, to rapidly and accurately identify bacterial pathogens[18] and *Candida* species[20] using a

commercial detection system present in clinical pathology laboratories primarily for oncological

use.[39–41] Here, we extended this approach to target 86 medically relevant fungi in our Pan-

Fungal Phirst-ID panel.

rRNA is an appealing target for hybridization-based identification due to its extreme

conservation within species,[42] and its high abundance, allowing amplification-free detection.

Experimental conditions for Phirst-ID only require base pairing, enabling detection from crude

lysate with <30 minutes hands-on time and no nucleic acid extraction or purification, with a total

assay time of <8 hours.[18] By comparison, we previously reported a median of 28 hours from

culture to identification for *Candida* bloodstream infections;[20] other fungi take longer to identify.

Unlike amplification-based methods, the lack of enzymology makes Phirst-ID compatible with

chemical RNase inhibitors for robust RNA stabilization. And whereas mass spectrometry-based

methods must contend with surface proteomes that can vary across the fungal life cycle [5,7,9,14]

rRNA is invariant.

Prior iterations of Phirst-ID identified organisms based on the closest Pearson correlation of

PSRPs of a query organism to that of organisms in a reference panel.[18,20] By contrast, upon

extending this approach to diverse fungal pathogens, we found that systematic variations in

probe intensity across the Pan-Fungal Phirst-ID panel led to avoidable errors using this

relatively simplistic classification scheme (**Fig. 4**). We therefore designed Co-PILOT, a classifier

that integrates Pearson correlations of full and partial PSRPs with known taxonomic

relationships between species to improve classification accuracy (**Fig. S4**). After iteratively

designing Co-PILOT based on a Training Set of 93 isolates across 32 species of common

fungal pathogens, Co-PILOT improved identification on an independent Validation Set of 54

isolates representing the same species compared with the simpler scheme. Two pairwise

misidentifications were made at the species level, each between close phylogenetic relatives:

Co-PILOT mistook *C. neoformans* for *C. gattii* and vice-versa, and *S. apiospermum* for *L.*

prolificans and vice-versa. Both errors appeared to be due to probes designed to distinguish

each pair, not performing as expected. In the former case, the distinction between *C.*

neoformans and *C. gattii* has minimal clinical consequences; though their geographic

distribution is somewhat distinct, and their propensity to infect immunocompetent patients may

somewhat differ, they both cause similar types of illness, with similar severity and management

options.[43] By contrast, the latter case is more clinically critical: though they cause a similar

spectrum of illness in similarly immunocompromised patients, the intrinsic antifungal resistance

profiles of *S. apiospermum* and *L. prolificans* differ meaningfully, leading to different empiric

therapies.[44,45] In order to distinguish these, iterations on the probeset would be required, and if

no rRNA-directed probe is able to make this clinically important distinction, mRNA targets may

be needed, at a cost of assay sensitivity; or a separate diagnostic test may be required.

In a pilot study to test additional clinical sample types on our Pan-Fungal Phirst-ID probeset, we

tested archived FFPE tissue samples containing fungal forms. This sample type is critical for

patient diagnosis when cultures are either not attempted or negative, or to identify species prior

to culture, which for fungi can take days to weeks.[1,5,6,37,38] FFPE tissue is optimized for

morphological examination, but molecular methods are increasingly used to identify

pathogens.[38] Typical workflows involve DNA extraction followed by rDNA-directed PCR with

amplicon sequencing, which generally has limited success, ranging from 13-34% in published

series,[46–50] typically worse for fungi.[47] Of the 27 FFPE samples we tested, 12 passed our

threshold of confidence (>1000 raw max probe counts); of these, Co-PILOT correctly identified

5 to the species level, 9 to the genus level, and one more to the closest available phylogenetic

match (**Fig. 6**). For 14 samples positive for fungal forms by microscopy, we were unable to

identify an organism due to lack of signal. Adding a bead beating step after deparaffinization

helped increase signal for some samples, but more work is required to optimize RNA extraction

for best results on this clinically important sample type, before testing head-to-head against the

current standard of practice.

This study has several limitations. First, although Pan-Fungal Phirst-ID was designed to detect

86 fungal pathogens, we have thus far only been able to rigorously test and independently

validate it against multiple isolates of 32 species. Its accuracy in identifying these 32 key

species should be well-predicted by its performance on our Validation Set and should improve

as the Training Set gets larger with further use. However, its performance on species not

included in this Training Set is uncertain. First, we did observe predictable recognition patterns

on an additional 18 species (**Fig. S2**), for which we were only able to obtain 1-2 examples for

testing. When trained on sufficient examples of new species, Pan-Fungal Phirst-ID should

perform well, as long as the 91 probes provide a unique PSRP. However, recognizing when an

off-panel species is encountered remains a key challenge. Second, although Pan-Fungal Phirst-

ID with Co-PILOT accurately identified >90% of clinical isolates samples to the species level

and 98% at the family level in an independent Validation Set, it clearly struggled with the

clinically relevant distinction between *S. apiospermum* and *L. prolificans*. Third, several isolates

in our Training and Validation Set were only identified to the genus level by the clinical

microbiology laboratory, and therefore Phirst-ID accuracy could only be measured to the genus

level. With further training, it is possible that species-level distinctions could be made, but

genus-level identification for these isolates meets or even exceeds current clinical laboratory

reporting standards for these genera (e.g., *Mucor*, *Rhizopus*, and *Cunninghamella* are often

reported as order *Mucorales* from clinical laboratories), whereas Pan-Fungal Phirst-ID

accurately identified them to the genus level - better than clinical morphology-based

assessments in at least one case (**Fig. S7**). Fourth, aside from the pilot on FFPE tissue, we thus

far only trained and tested this assay on monocultures. Although *Candida* Phirst-ID was able to

recognize mixed cultures as linear combinations of PSRPs from each species,[20] the increased

complexity of PSRPs in the Pan-Fungal probeset will likely make this more challenging. Fifth, in

this initial work, we rigorously tested this assay primarily on cultured isolates, although the

hybridization-based assay in other contexts has worked well despite an excess of off-target

nucleic acids (such as human tissue). Still, despite some promising results on a small number of

pilot samples, further optimization is needed for deployment on primary clinical samples,

including the high-value clinical use case of FFPE tissue. Finally, this assay is currently

research-use-only, like its bacterial and *Candida* counterparts. However, this broad-range,

sensitive assay could be readily applied to agricultural, environmental or biodefense monitoring.

It would be feasible to combine our bacterial probeset[18] with this Pan-Fungal probeset to

characterize complex samples or polymicrobial infection.[20] Additional work beyond the scope of

our academic laboratory would be required to optimize process and reagents, and ideally

automate portions of the workflow, prior to broader scope implementation. Once optimized and

scaled, Pan-Fungal Phirst-ID offers a novel approach to fungal identification that combines the

lack of enzymology of mass spectrometry with the invariant and high-abundance targets of

rRNA-based methods, implementable on either cultured isolates or primary specimens.

Acknowledgments:

We thank Dr. Sinem Beyhan and Jacob Durazo from the J. Craig Venter Institute, Dr. Joseph Kovacs, Dr. Shelly Curran, and Dr. Liang Ma from the NIH for generously sharing samples with us, and Andrew Grootsky, Aleksandr Kutchma, Richard Boykin (current or former employees of NanoString, now Bruker Spatial Biology, the company that manufactures the RNA detection platform used in this manuscript) for their assistance with our non-standard probe design. This work was supported in part by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health [grant numbers 1R01AI153405 to R.P.B. and C.A.C., and T32 AI007061 to E.A.Y]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection, and interpretation, or decision to submit this work for publication. R.P.B, E.A.Y and M.L.D-M are co-inventors on subject matter in BI-11335, and R.P.B is a co-inventor on subject matter in BI-11339, filed by the Broad Institute directed to methodology of identifying fungal pathogens using rRNA and disclosure of fungal probes, respectively, as described in this manuscript.

Figure 1. Phylogenetic coverage of Pan-Fungal Phirst-ID probeset. Fungal species included in
probeset design, arranged by maximum-likelihood phylogeny inferred using IQ-TREE. To the right of
each species, each solo square or set of connected squares denotes a unique probe; black lines
connecting squares indicate a single probe designed to target multiple species within a taxonomic group.
Colors indicate taxonomic level of the probes (see key at bottom left). For each level, squares at left
indicate an 18S rRNA target and at right a 28S rRNA target. Tree branch lengths are in expected
substitutions per site.

Figure 2. Pan-Fungal Phirst-ID panel generates unique PSRPs for 33 clinically relevant species.
Heatmap shows scaled binding intensities of 91 probes (vertical axis) tested against the Training Set of
94 samples from 33 species (horizontal axis). Taxonomic level of each probe is indicated by colored box
at left (numbers in parentheses = total probes designed at each level); probe name is listed at right. Each
axis is ordered by taxonomic hierarchy, with species displayed in a cladogram. Horizontal black bars with
dots indicate unique isolates of each species tested; vertical lines indicate transitions between species.
Purple boxes indicate regions where the class of samples and intended probe targets match.

604
Figure 3. Pan-Fungal Phirst-ID PSRPs identify most species. Leave-one-out analysis of Training Set
data showing closest taxonomic matches based on highest Pearson correlation. **(A)** Tile plot indicating
accuracy of best non-self matches within the Training Set for identifying each individual isolate at each
taxonomic level. **(B)** Dot plot of Pearson correlations of each indicated sample against all other samples
in the Training Set, colored by closest-matched taxonomic level of the comparator. When the species of a
test strain was unknown, the best possible match is to the genus level, indicated by a gray box at the
species level in (A), and by a black circle with red border in (B).

A

B

627
628 **Figure 4. Probes designed for regions conserved at higher taxonomic levels exhibit higher**
629 **binding signal.** Violin plots of normalized signal intensity of probes targeting each taxonomic level of **(A)**
630 all samples in Training Set and **(B)** only *Aspergillus* samples in Training Set. Y-axis for both graphs
631 indicates non-zero probe reactivities normalized to the maximally reactive probe for each sample.

647
648
Figure 5: Pan-Fungal Phirst-ID PSRPs identify most species in independent Validation Set. Each
sample in the Validation Set was compared by Pearson correlation with that of the entire Training Set. **(A)**
Tile plot indicating accuracy of best matches at each taxonomic level based on highest Pearson
correlation. **(B)** Dot plot of Pearson correlations of each Validation sample against all samples in the
Training Set, colored by closest taxonomic level of the comparator. **(C)** Tile plot shows that Co-PILOT
improves accuracy relative to simple Pearson correlations (A) for identifying the best match. When the
species of a test strain was unknown, the best possible match is to the genus level, indicated by a gray
tile at the species level in (A and C), and by a black circle with red border in (B).

Clinical Identification

673
Figure 6. Pilot application of Pan-Fungal Phirst-ID to FFPE samples. Tile plot indicating prediction
accuracy at each taxonomic level for the subset of FFPE samples with high enough probe reactivity to
pass our threshold for Co-PILOT analysis. Sample order is based the highest probe read count (green
heatmap), which was used to set this threshold. Red heatmap shows Pearson correlation of each sample
to its best match. Clinical laboratory identifications are listed below (see Table S3c); red text indicates an
organism not previously tested by Pan-Fungal Phirst-ID (and thus not available to Co-PILOT algorithm for
comparison), green text = negative control FFPE sample (no fungal forms seen).

690
691
692 **Figure S1. Coverage maps of Pan-Fungal Phirst-ID probe sequences along 18S and 28S rRNA**
693 **subunits.** Probe sequences mapped along target rRNA sequence of (A) 18S and (B) 28S subunits. Color
694 of line indicates taxonomic level specificity of probe. Longer mappings indicate gaps in alignment due to

695   genetic variation in the consensus sequence. Light gray vertical lines indicate 500 bp distance along the
696   consensus 18/28S axes (including gaps). Probe sequences are available in Supplementary Table S2.

708
709 **Figure S2 Pan-Fungal Phirst-ID PSRPs against additional samples not included in the Training**
710 **Set.** Heatmap displaying normalized probe binding intensities of 24 additional samples, for which we were
711 only able to obtain 1 or 2 examples and thus did not meet criteria for inclusion in the Training or Validation
712 Sets (because we could not rigorously apply our sample identification algorithms). Purple boxes indicate
713 regions where the class of samples and intended probe targets match.

724
725
Figure S3. Pearson correlations of Training Set PSRPs are highest between closely related
species. Samples with similar taxonomic classification had higher pairwise Pearson correlations than
those that were more dissimilar. **(A)** Tile plot indicates prediction accuracy for the single best-matched
(highest) non-self-Pearson correlation at each taxonomic level, as in Fig 3a. **(B)** Heatmap of pairwise
Pearson correlations, showing that the highest correlations map to members of closely related species.
Training Set samples are ordered by taxonomic classification as in Fig 2.

739
740

Figure S4. Schematic of our hierarchical Pearson correlation classifier Co-PILOT. Visual
representation of how Co-PILOT moves through taxonomic levels, demonstrated on an *Aspergillus
fumigatus* sample. Co-PILOT begins by considering all probes and samples **(A)**, and chooses the best-
matched class based on the class of the single (non-self) sample with the highest Pearson correlation to
the query sample. It then restricts further analysis to only samples from that class, and only probes
nested within that class (i.e., those designed to target regions matching an order, family, genus, or
species within the selected class), indicated by the box (colored by taxonomic level, as in other figures;
here, purple box = class); data from all other samples and probes are removed at this stage **(B)**, including
probe(s) matching selected class. In subsequent steps, Co-PILOT selects only the subset of samples &
probe(s) containing the best-matched order (B → C, blue box), family (C → D, green box), and genus (D
→ E, orange box). Top panels = read count heatmaps, rescaled by sample at each step to maximize
remaining probe; bottom panels = Pearson correlation heatmaps only using selected data at each step.

771
Figure S5. The Co-PILOT classifier improved identification accuracy of the Pan-Fungal Phirst-ID
probeset on Training Set. Tile plot indicating prediction accuracy at each taxonomic level, as in Fig 3a.
Co-PILOT (bottom panel) improved accuracy relative to simple Pearson correlations (top panel), though it
was iteratively designed based on the Training Set, so these results are best viewed as "overtrained" -
see main text and Methods for details. By contrast, its performance on the Validation Set (Fig 6) is an
independent assessment of Co-PILOT's accuracy on data it had not seen until its algorithm (Supp Fig S4)
was fully designed.
779
780

781
782 **Figure S6. Pan-Fungal Phirst-ID panel generates unique PSRPs for 32 clinically relevant species in**
783 **our Validation Set.** Heatmap of scaled binding intensities of the 54 samples comprising our Validation
784 Set. As in Figure 2, samples and probes are ordered taxonomically, though the cladogram is omitted
785 here. Taxonomic level of each probe is indicated by colored box at left; probe name is listed at right.
786 Purple boxes indicate regions where the class of samples and intended probe targets match.
787
788
789
790

Figure S7 Errant clinical identification of *Mucor* from Validation Set. Pan-Fungal Phirst-ID data from all probes targeting subsets of the *Mucoromycetes* class, shown for all samples from the Training and Validation Sets identified by the clinical microbiology laboratory as either *Mucor* or *Rhizopus*. The red label indicates a Validation sample identified by the clinical laboratory as a *Mucor*, but with a PSRP better resembling a *Rhizopus* (specifically in the lack of Mucor_18S probe reactivity, and perhaps greater R_oryzae_18S probe reactivity). ITS sequencing identified this sample as *Rhizopus microsporus*, more consistent with the Pan-Fungal Phirst-ID prediction than the clinical classification.

801
Figure S8. Representative hematoxylin and eosin (H&E)-stained sections from formalin-fixed,
paraffin-embedded tissues included in the study (A) Lung tissue, negative control (Fig S9, right panel,
column 11; Supp Table S3d, sample FP002). **(B)** Aortic valve tissue with *Candida parapsilosis* (Fig S9,
left panel, column 7; Supp Table S3d, sample FP024. **(C)** Lung tissue with *Cryptococcus neoformans* (Fig
S9, right panel, column 8; Supp Table S3d, sample FP011). **(D)** Lung tissue with *Coccidioides* sp (Fig S9,
right panel, column 4; Supp Table S3d, sample FP019. **(E)** Sinus tissue with *Aspergillus fumigatus* (Fig
S9, left panel, column 5; Supp Table S3d, sample FP028). **(F)** Sinus tissue with *Rhizopus* sp (Fig S9,
right panel, column 15; Supp Table S3d, sample FP023). All images were acquired using a 40× objective.

Figure S9: Pilot use of Pan-Fungal Phirst ID for FFPE samples **(A)** Heatmap of scaled probe binding
intensities of 27 FFPE samples. For column-scaling to better visually represent total read counts, the four
lowest-abundance positive control spike-ins are included for each sample (top 4 rows, above horizontal
line). Bottom axis indicates clinical identification provided by the Pathology department (see
Supplementary Table S3d). **(B)** Tile plot indicating prediction accuracy of Pan-Fungal Phirst-ID with Co-
PILOT at each taxonomic level, as in Fig 3a. Date of sample collected is indicated above and final Co-
PILOT identification (best match from Training Set) is listed below the tile plot. 12 samples at left, which
exceeded our probe detection threshold, are separated from 17 samples at right, which did not. For
visualization purposes, all samples are scaled to the third-most-abundant positive control spike-in (shown
above black horizontal line at top). Samples are sorted by taxonomic order of the identification from the
clinical microbiology laboratory.
822

Cited Works

1. Almeida, F., Rodrigues, M. L., & Coelho, C. (2019). The Still Underestimated Problem of

Fungal Diseases Worldwide. *Frontiers in Microbiology*, *10*.

https://doi.org/10.3389/fmicb.2019.00214

2. Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014).

Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections. *Clinical*

Microbiology Reviews, *27*(3), 490–526. https://doi.org/10.1128/CMR.00091-13

3. Zhang, S. X., Babady, N. E., Hanson, K. E., Harrington, A. T., Larkin, P. M. K., Leal, S.

M., Luethy, P. M., Martin, I. W., Pancholi, P., Procop, G. W., Riedel, S., Seyedmousavi, S.,

Sullivan, K. V., Walsh, T. J., & Lockhart, S. R. (2021). Recognition of Diagnostic Gaps for

Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics

Laboratories Consortium (FDLC). *Journal of Clinical Microbiology*, *59*(7), e01784-20.

https://doi.org/10.1128/JCM.01784-20

4. Badiee, P., & Hashemizadeh, Z. (2014). Opportunistic invasive fungal infections:

Diagnosis & clinical management. *The Indian Journal of Medical Research*, *139*(2), 195–

204.

5. Kozel, T. R., & Wickes, B. (2014). Fungal diagnostics. *Cold Spring Harbor Perspectives*

in Medicine, *4*(4), a019299. https://doi.org/10.1101/cshperspect.a019299

6. Barnes, R. A. (2008). Early diagnosis of fungal infection in immunocompromised

patients. *Journal of Antimicrobial Chemotherapy*, *61*(Supplement 1), i3–i6.

https://doi.org/10.1093/jac/dkm424

7. Freeman Weiss, Z., Leon, A., & Koo, S. (2021). The Evolving Landscape of Fungal

Diagnostics, Current and Emerging Microbiological Approaches. *Journal of Fungi*, *7*(2), 127.

https://doi.org/10.3390/jof7020127

8. Hage, C. A., Carmona, E. M., Epelbaum, O., Evans, S. E., Gabe, L. M., Haydour, Q.,

Knox, K. S., Kolls, J. K., Murad, M. H., Wengenack, N. L., & Limper, A. H. (2019).

Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and

Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline.

American Journal of Respiratory and Critical Care Medicine, *200*(5), 535–550.

https://doi.org/10.1164/rccm.201906-1185ST

9. Wickes, B. L., & Wiederhold, N. P. (2018). Molecular diagnostics in medical mycology.

Nature Communications, *9*(1), 5135. https://doi.org/10.1038/s41467-018-07556-5

10. Theel, E. S., & Doern, C. D. (2013). Point-Counterpoint: β- D -Glucan Testing Is

Important for Diagnosis of Invasive Fungal Infections. *Journal of Clinical Microbiology*,

51(11), 3478–3483. https://doi.org/10.1128/JCM.01737-13

11. Yaman, G., Akyar, I., & Can, S. (2012). Evaluation of the MALDI TOF-MS method for

identification of Candida strains isolated from blood cultures. *Diagnostic Microbiology and

Infectious Disease*, *73*(1), 65–67. https://doi.org/10.1016/j.diagmicrobio.2012.01.013

12. Lau, A. F. (2021). Matrix-Assisted Laser Desorption Ionization Time-of-Flight for Fungal

Identification. *Clinics in Laboratory Medicine*, *41*(2), 267–283.

https://doi.org/10.1016/j.cll.2021.03.006

13. Huang, Y., Zhang, M., Zhu, M., Wang, M., Sun, Y., Gu, H., Cao, J., Li, X., Zhang, S.,

Wang, J., & Lu, X. (2017). Comparison of two matrix-assisted laser desorption ionization-

time of flight mass spectrometry systems for the identification of clinical filamentous fungi.

World Journal of Microbiology and Biotechnology, *33*(7), 142.

https://doi.org/10.1007/s11274-017-2297-3

14. Klugherz, I., Kölli, B., Reinmüller, M., Willinger, B., Leitner, E., Steinmetz, I., & Dichtl, K.

(2025). Identification of Filamentous Fungi: An Evaluation of Three MALDI - TOF Mass

Spectrometry Systems. *Mycoses*, *68*(6), e70078. https://doi.org/10.1111/myc.70078

15. Kurtzman, C. P., & Robnett, C. J. (1998). Identification and phylogeny of ascomycetous

yeasts from analysis of nuclear large subunit (26S) ribosomal DNA partial sequences.

Antonie van Leeuwenhoek, *73*(4), 331–371. https://doi.org/10.1023/A:1001761008817

16. Cathy A. Petti, MD, Mary E. Brandt, PhD, Deirdre L. Church, MD, PhD, D(ABMM),

Stefan Emler, MD, Keith Simmon, MS, PhD, & Adrian M. Zelazny, PhD, D(ABMM). (2018).

Interpretive Criteria for Identification of Bacteria and Fungi by Targeted DNA Sequencing

(2nd ed.). Clinical and Laboratory Standards Institute (CLSI).

https://clsi.org/shop/standards/mm18/

17. Alanio, A., & Bretagne, S. (2014). Difficulties with molecular diagnostic tests for mould

and yeast infections: Where do we stand? *Clinical Microbiology and Infection*, *20*, 36–41.

https://doi.org/10.1111/1469-0691.12617

18. Bhattacharyya, R. P., Walker, M., Boykin, R., Son, S. S., Liu, J., Hachey, A. C., Ma, P.,

Wu, L., Choi, K., Cummins, K. C., Benson, M., Skerry, J., Ryu, H., Wong, S. Y., Goldberg,

M. B., Han, J., Pierce, V. M., Cosimi, L. A., Shoresh, N., … Hung, D. T. (2019). Rapid

identification and phylogenetic classification of diverse bacterial pathogens in a multiplexed

hybridization assay targeting ribosomal RNA. *Scientific Reports*, *9*(1), 4516.

https://doi.org/10.1038/s41598-019-40792-3

19. Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H.

P., Ferree, S., George, R. D., Grogan, T., James, J. J., Maysuria, M., Mitton, J. D., Oliveri,

P., Osborn, J. L., Peng, T., Ratcliffe, A. L., Webster, P. J., Davidson, E. H., … Dimitrov, K.

(2008). Direct multiplexed measurement of gene expression with color-coded probe pairs.

Nature Biotechnology, *26*(3), 317–325. https://doi.org/10.1038/nbt1385

20. Matzko, M. E., Sephton-Clark, P. C. S., Young, E. L., Jhaveri, T. A., Martinsen, M. A.,

Mojica, E., Boykin, R., Pierce, V. M., Cuomo, C. A., & Bhattacharyya, R. P. (2022). A novel

rRNA hybridization-based approach to rapid, accurate *Candida* identification directly from

blood culture. *Medical Mycology*, *60*(9), myac065. https://doi.org/10.1093/mmy/myac065

21. Voorhies, M., Cohen, S., Shea, T. P., Petrus, S., Muñoz, J. F., Poplawski, S., Goldman,

W. E., Michael, T. P., Cuomo, C. A., Sil, A., & Beyhan, S. (2022). Chromosome-Level

Genome Assembly of a Human Fungal Pathogen Reveals Synteny among Geographically

Distinct Species. *mBio*, *13*(1), e02574-21. https://doi.org/10.1128/mbio.02574-21

22. Cuomo, C. A., Rodriguez-Del Valle, N., Perez-Sanchez, L., Abouelleil, A., Goldberg, J.,

Young, S., Zeng, Q., & Birren, B. W. (2014). Genome Sequence of the Pathogenic Fungus

Sporothrix schenckii (ATCC 58251). *Genome Announcements*, *2*(3), e00446-14.

https://doi.org/10.1128/genomeA.00446-14

23. Sephton-Clark, P., Nguyen, T., Hoa, N. T., Ashton, P., van Doorn, H. R., Ly, V. T., Le,

T., & Cuomo, C. A. (2023). Impact of pathogen genetics on clinical phenotypes in a

population of Talaromyces marneffei from Vietnam. *Genetics*, *224*(4), iyad100.

https://doi.org/10.1093/genetics/iyad100

24. Muñoz, J. F., Gauthier, G. M., Desjardins, C. A., Gallo, J. E., Holder, J., Sullivan, T. D.,

Marty, A. J., Carmen, J. C., Chen, Z., Ding, L., Gujja, S., Magrini, V., Misas, E., Mitreva, M.,

Priest, M., Saif, S., Whiston, E. A., Young, S., Zeng, Q., … Cuomo, C. A. (2015). The

Dynamic Genome and Transcriptome of the Human Fungal Pathogen Blastomyces and

Close Relative Emmonsia. *PLoS Genetics*, *11*(10), e1005493.

https://doi.org/10.1371/journal.pgen.1005493

25. Muñoz, J. F., Gallo, J. E., Misas, E., Priest, M., Imamovic, A., Young, S., Zeng, Q., Clay,

O. K., McEwen, J. G., & Cuomo, C. A. (2014). Genome update of the dimorphic human

pathogenic fungi causing paracoccidioidomycosis. *PLoS Neglected Tropical Diseases*,

8(12), e3348. https://doi.org/10.1371/journal.pntd.0003348

26. Hudson, J., Budvytiene, I., & Banaei, N. (2025). Diagnostic stewardship applied to

targeted fungal sequencing. *Journal of Clinical Microbiology*, *63*(10), e00896-25.

https://doi.org/10.1128/jcm.00896-25

27. Leaw, S. N., Chang, H. C., Sun, H. F., Barton, R., Bouchara, J.-P., & Chang, T. C.

(2006). Identification of Medically Important Yeast Species by Sequence Analysis of the

Internal Transcribed Spacer Regions. *Journal of Clinical Microbiology*, *44*(3), 693–699.

https://doi.org/10.1128/JCM.44.3.693-699.2006

28. Abarenkov, K., Nilsson, R. H., Larsson, K.-H., Taylor, A. F. S., May, T. W., Frøslev, T.

G., Pawlowska, J., Lindahl, B., Põldmaa, K., Truong, C., Vu, D., Hosoya, T., Niskanen, T.,

Piirmann, T., Ivanov, F., Zirk, A., Peterson, M., Cheeke, T. E., Ishigami, Y., … Kõljalg, U.

(2024). The UNITE database for molecular identification and taxonomic communication of

fungi and other eukaryotes: Sequences, taxa and classifications reconsidered. *Nucleic*

Acids Research, *52*(D1), D791–D797. https://doi.org/10.1093/nar/gkad1039

29. Poplin, V., Smith, C., Caceres, D. H., Herkert, P. F., Jegede, O., Thompson, G. R.,

Baddley, J. W., Schwartz, I. S., Kubat, R., Deka, M. A., Toda, M., Lockhart, S. R., Chiller, T.,

Hagen, F., & Bahr, N. C. (2024). Geographical distribution of the Cryptococcus gattii species

complex: A systematic review. *The Lancet. Microbe*, *5*(12), 100921.

https://doi.org/10.1016/S2666-5247(24)00161-7

30. Kwon-Chung, K. J., Bennett, J. E., Wickes, B. L., Meyer, W., Cuomo, C. A., Wollenburg,

K. R., Bicanic, T. A., Castañeda, E., Chang, Y. C., Chen, J., Cogliati, M., Dromer, F., Ellis,

D., Filler, S. G., Fisher, M. C., Harrison, T. S., Holland, S. M., Kohno, S., Kronstad, J. W., …

Casadevall, A. (2017). The Case for Adopting the "Species Complex" Nomenclature for the

Etiologic Agents of Cryptococcosis. *mSphere*, *2*(1), e00357-16.

https://doi.org/10.1128/mSphere.00357-16

31. Lackner, M., De Hoog, G. S., Yang, L., Ferreira Moreno, L., Ahmed, S. A., Andreas, F.,

Kaltseis, J., Nagl, M., Lass-Flörl, C., Risslegger, B., Rambach, G., Speth, C., Robert, V.,

Buzina, W., Chen, S., Bouchara, J.-P., Cano-Lira, J. F., Guarro, J., Gené, J., … Liporagi

Lopes, L. C. (2022). Proposed nomenclature for Pseudallescheria, Scedosporium and

related genera. *Fungal Diversity, 113*(1), 193–194. https://doi.org/10.1007/s13225-022-

00505-0

32. Sangoi, A. R., Rogers, W. M., Longacre, T. A., Montoya, J. G., Baron, E. J., & Banaei, N.

(2009). Challenges and Pitfalls of Morphologic Identification of Fungal Infections in

Histologic and Cytologic Specimens. *American Journal of Clinical Pathology, 131*(3), 364–

375. https://doi.org/10.1309/AJCP99OOOZSNISCZ

33. Safiia, J., Díaz, M. A., Alshaker, H., Atallah, C. J., Sakr, P., Moshovitis, D. G., Nawlo, A.,

Franceschi, A. E., Liakos, A., & Koo, S. (2024). Recent Advances in Diagnostic Approaches

for Mucormycosis. *Journal of Fungi, 10*(10), 727. https://doi.org/10.3390/jof10100727

34. Mathieson, W., & Thomas, G. A. (2020). Why Formalin-fixed, Paraffin-embedded

Biospecimens Must Be Used in Genomic Medicine: An Evidence-based Review and

Conclusion. *The Journal of Histochemistry and Cytochemistry: Official Journal of the*

Histochemistry Society, 68(8), 543–552. https://doi.org/10.1369/0022155420945050

35. Fox, C. H., Johnson, F. B., Whiting, J., & Roller, P. P. (1985). Formaldehyde fixation.

The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry

Society, 33(8), 845–853. https://doi.org/10.1177/33.8.3894502

36. Guarner, J., & Brandt, M. E. (2011). Histopathologic Diagnosis of Fungal Infections in

the 21st Century. *Clinical Microbiology Reviews, 24*(2), 247–280.

https://doi.org/10.1128/CMR.00053-10

37. Cabaret, O., Toussain, G., Abermil, N., Alsamad, I. A., Botterel, F., Costa, J.-M., Papon,

J.-F., & Bretagne, S. (2011). Degradation of fungal DNA in formalin-fixed paraffin-embedded

sinus fungal balls hampers reliable sequence-based identification of fungi. *Medical*

Mycology, 49(3), 329–332. https://doi.org/10.3109/13693786.2010.525537

38. Gomez, C. A., Budvytiene, I., Zemek, A. J., & Banaei, N. (2017). Performance of

Targeted Fungal Sequencing for Culture-Independent Diagnosis of Invasive Fungal

Disease. *Clinical Infectious Diseases, 65*(12), 2035–2041. https://doi.org/10.1093/cid/cix728

39. Lænkholm, A.-V., Jensen, M.-B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S.,

Buckingham, W., Ferree, S., Schaper, C., Nielsen, T. O., Haffner, T., Kibøl, T., Møller

Talman, M.-L., Bak Jylling, A. M., Tabor, T. P., & Ejlertsen, B. (2018). PAM50 Risk of

Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort

of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone

Receptor–Positive Early Breast Cancer. *Journal of Clinical Oncology*, *36*(8), 735–740.

https://doi.org/10.1200/JCO.2017.74.6586

40. Costa, R. L. B., & Gradishar, W. J. (2018). Do Genomic Assays Provide the Necessary

Confidence to De-escalate Adjuvant Therapy? *Journal of Clinical Oncology*, *36*(8), 725–727.

https://doi.org/10.1200/JCO.2017.76.9802

41. Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., Greil, R.,

Dubsky, P., Stoeger, H., Rudas, M., Jakesz, R., Ferree, S., Cowens, J. W., Nielsen, T.,

Schaper, C., Fesl, C., & Cuzick, J. (2015). Identifying clinically relevant prognostic

subgroups of postmenopausal women with node-positive hormone receptor-positive early-

stage breast cancer treated with endocrine therapy: A combined analysis of ABCSG-8 and

ATAC using the PAM50 risk of recurrence score and intrinsic subtype. *Annals of Oncology*,

26(8), 1685–1691. https://doi.org/10.1093/annonc/mdv215

42. Khot, P. D., Ko, D. L., & Fredricks, D. N. (2009). Sequencing and analysis of fungal

rRNA operons for development of broad-range fungal PCR assays. *Applied and*

Environmental Microbiology, *75*(6), 1559–1565. https://doi.org/10.1128/AEM.02383-08

43. Kwon-Chung, K. J., Fraser, J. A., Doering, T. L., Wang, Z., Janbon, G., Idnurm, A., &

Bahn, Y.-S. (2014). Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents

of cryptococcosis. *Cold Spring Harbor Perspectives in Medicine*, *4*(7), a019760.

https://doi.org/10.1101/cshperspect.a019760

44. Wu, Y., Grossman, N., Totten, M., Memon, W., Fitzgerald, A., Ying, C., & Zhang, S. X.

(2020). Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical

1021 Lomentospora prolificans Isolates. *Antimicrobial Agents and Chemotherapy*, *64*(11),

1022 e00318-20. https://doi.org/10.1128/AAC.00318-20

1023 45. Chen, S. C.-A., Halliday, C. L., Hoenigl, M., Cornely, O. A., & Meyer, W. (2021).

1024 Scedosporium and Lomentospora Infections: Contemporary Microbiological Tools for the

1025 Diagnosis of Invasive Disease. *Journal of Fungi*, *7*(1), 23.

1026 https://doi.org/10.3390/jof7010023

1027 46. Aggarwal, D., Kanitkar, T., Narouz, M., Azadian, B. S., Moore, L. S. P., & Mughal, N.

1028 (2020). Clinical utility and cost-effectiveness of bacterial 16S rRNA and targeted PCR based

1029 diagnostic testing in a UK microbiology laboratory network. *Scientific Reports*, *10*(1), 7965.

1030 https://doi.org/10.1038/s41598-020-64739-1

1031 47. Kubiak, J., Morgan, A., Kirmaier, A., Arnaout, R., & Riedel, S. (2023). Universal PCR for

1032 bacteria, mycobacteria, and fungi: A 10-year retrospective review of clinical indications and

1033 patient outcomes. *Journal of Clinical Microbiology*, *61*(12), e00952-23.

1034 https://doi.org/10.1128/jcm.00952-23

1035 48. Kerkhoff, A. D., Rutishauser, R. L., Miller, S., & Babik, J. M. (2020). Clinical Utility of

1036 Universal Broad-Range Polymerase Chain Reaction Amplicon Sequencing for Pathogen

1037 Identification: A Retrospective Cohort Study. *Clinical Infectious Diseases*, *71*(6), 1554–1557.

1038 https://doi.org/10.1093/cid/ciz1245

1039 49. Naureckas Li, C., & Nakamura, M. M. (2022). Utility of Broad-Range PCR Sequencing

1040 for Infectious Diseases Clinical Decision Making: A Pediatric Center Experience. *Journal of*

1041 *Clinical Microbiology*, *60*(5), e02437-21. https://doi.org/10.1128/jcm.02437-21

1042 50. Weinert-Stein, K., Cater, M., Cherian, S. S., Azem, R., Khazan, A. E., Desai, A. P.,

1043 Tripp, L., Lim, P. P., Stempak, L. M., & Hojat, L. S. (2024). Clinical Utility of Broad-Range

1044 PCR Testing and Impact on Outcomes in Adults with Suspected Infection. *Antibiotics*,

1045 *13*(12), 1166. https://doi.org/10.3390/antibiotics13121166

1046